Next-Generation Arize Element® L1000 Enables Efficient Growth at an Industrial Scale
27.9.2021 21:06:00 EEST | Business Wire | Press release
GE Current, a Daintree company, today introduced the next generation of the Arize Element L1000, a top light for commercial greenhouses and indoor farms. The next generation features three models with expanded spectral options, a high photon flux of up to 2,350 μmol/s, high efficacy levels of up to 3.6 µmol/J and is proudly assembled in the heart of Appalachia.
“We set out to engineer the world’s most rugged and durable light fixture for commercial agriculture, thanks to our 20-plus years of LED fixture design experience combined with over 65 years of manufacturing excellence and scale in Hendersonville, North Carolina,” said Mike Doss, Current’s VP of Specialty. “We’ve improved the Element in every possible way, from light intensity to efficacy, and now it is proudly assembled in the Appalachians.”
The Element family now features eight spectral options in three all-new models:
- L1000: The L1000 is a flexible, all-purpose fixture, with a PPF of up to 1900 µmol/s at 3.3 µmol/J.
- L1000 HE: The L1000 HE (high efficiency) emits 1900 µmol/s at 3.6 µmol/J, for large-scale commercial greenhouses.
- L1000 HO: The L1000 HO (high output) offers the best of both worlds: PPF levels of up to 2350 µmol/s at 3.4 µmol/J.
The Element family features Current’s proprietary XW Optic, which precisely targets light dispersion, resulting in wider coverage in low headspace applications. It reduces the number of fixtures needed by 10 to 15% without sacrificing uniformity or crop quality, lowering capital investment. The mounting options have also been simplified, with the fixture and power supply sharing common mounting hardware.
Powering Opportunities in Appalachia
Proudly assembled in Hendersonville, North Carolina, the new Arize Element L1000 has been selected by AppHarvest (NASDAQ: APPH) for its new Morehead, Kentucky, farm, slated to open later this year.
“As a grower, we have to consider several factors to maximize crop production and yield. One factor we pay close attention to is the management of light,” said Jose “Pepe” Calderon, Head Grower, AppHarvest. “With the Current LED grow lights, we have found several advantages such as dimmable intensities and energy efficiency, giving us the benefits for higher production, plant development, earlier crops, better climate control and energy savings.”
Learn more about Current’s newest top lighting solution at www.gecurrent.com/horticulture.
About GE Current, a Daintree company:
Current enhances commercial, industrial, city and specialty applications with advanced lighting and intelligent controls. Working with our partners, we deliver the best possible outcomes for our customers. See why Current is always on at www.gecurrent.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210927005730/en/
Contact information
Jim Benson
james.benson@gecurrent.com
216-534-4155
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Fujirebio Expands Access in Canada to Blood-based Neurology Testing with Health Canada Class II Medical Device Licenses for the Lumipulse® G NfL Blood and Lumipulse G pTau 217 Plasma Assays1.9.2026 08:00:00 EEST | Press release
H.U. Group Holdings Inc. and its wholly owned subsidiary Fujirebio today announced that Health Canada has issued Class II Medical Device Licenses (MDL) for the Lumipulse G NfL Blood and the Lumipulse G pTau 217 Plasma assay for use on the fully automated LUMIPULSE® G immunoassay platform in the Canadian market. "The approval of the Lumipulse G NfL Blood and Lumipulse G pTau 217 Plasma assays for clinical use in Canada marks another important step in our mission to expand access to reliable and clinically meaningful blood-based biomarkers for clinicians and patients worldwide," said Christiaan De Wilde, CEO of Fujirebio Europe N.V. “As a pioneer in neurological diagnostics, Fujirebio remains committed to advancing patient care through innovative, fully automated testing solutions." These approvals further strengthen Fujirebio’s comprehensive neurological diagnostics portfolio by broadening access to high-quality biomarker solutions designed to inform clinical decision-making across the
Helical Fusion Named a Final Candidate for Japan’s METI Fusion Power Demonstration Program1.9.2026 05:00:00 EEST | Press release
Helical Fusion Co., Ltd., a fusion energy company developing a Helical Stellarator toward commercially viable fusion power, has been named a final candidate for Japan’s Ministry of Economy, Trade and Industry (METI) program supporting the demonstration of fusion power generation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260831991676/en/ Image of Helix HARUKA, Helical Fusion’s Integrated Demo Device(left), and Helix KANATA, Helical Fusion’s Fusion Pilot Plant(right) The program is designed to accelerate fusion power demonstration in the 2030s under Japan’s national energy and fusion strategies. It supports private-sector technology development across multiple fusion approaches, including tokamak, stellarator and laser fusion, with approximately JPY 60 billion in total government support anticipated over the three years through 2028. The amount to be awarded to Helical Fusion will be announced following the formal grant
Strategic Combination of ITC Infotech and Happiest Minds Technologies to Create a Scaled, Future-Ready, AI-First Global Technology Services Enterprise with US$ 1 Billion Revenue by FY28 [1]1.9.2026 00:35:00 EEST | Press release
ITC Infotech (ITCI), a wholly owned subsidiary of ITC Limited and a leading global technology services player, today announced the proposed strategic combination with Happiest Minds Technologies Limited (Happiest Minds) to create a scaled, future-ready, AI-first global technology services enterprise. The ITCI Board approved a proposal to acquire 22.1% equity stake from the promoter of Happiest Minds in two tranches under a Share Purchase Agreement. The transaction would be funded through a Rights Issue by ITC Infotech. ITCI Board has also approved a proposed Scheme of Amalgamation of Happiest Minds with ITCI which will be effected after the share acquisition. Pursuant to the scheme, the shares of ITCI will be listed on the stock exchanges. The proposed transaction has also been endorsed by the Board of Directors of ITC Limited. This strategic combination will synergistically blend ITCI’s AI-led capabilities across Cloud, Data Analytics, PLM, SAP, enterprise transformation, industry-spe
Angel’s Profits Grew Robustly in the First Half of 2026 with Europe and North America Turning Profitable Ahead of Schedule31.8.2026 22:07:00 EEST | Press release
Angelalign Technology Inc. (“Angel” or the “Company”) (6699.HK) (angelaligner.com), the second largest clear aligner supplier by revenue, announced today that its revenue grew 42.9% to US$230.7 million and net profit grew 79.6% to $25.5 million for the six months ending June 30, 2026. Angel’s business in Europe and North America crossed into profitability ahead of plan while the business in Chinese mainland delivered market share gains well above expectations. Doctors and staff in every region report that they are increasingly selecting Angel’s solutions after experiencing more predictable outcomes, especially on complex cases, and embracing the positive culture of the company. Dr. Mark Holt D.D.S., M.S. of Holt Orthodontics in Northern California, states: “We treat over half of our patients with clear aligners and our experience with Angel’s treatment plans and clear aligners has been tremendous.” “Our main focus is to provide great service to and being a rock-solid partner for our cu
BeOne Medicines Announces Voluntary Agreement with U.S. Government to Expand Access to Innovative Cancer Medicines31.8.2026 22:00:00 EEST | Press release
BeOne Medicines, Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced a voluntary agreement with the U.S. Government to expand access to innovative cancer medicines for American patients while strengthening our U.S manufacturing footprint and further expanding the capabilities needed to deliver medicines at scale. The agreement builds on BeOne's longstanding commitment to patient access and investment in research and scientific innovation. John V. Oyler, Co-Founder, Chairman and CEO, BeOne Medicines, said: “At BeOne, we believe every patient should benefit from innovative cancer therapies. We appreciate the Trump Administration’s commitment to advancing solutions that broaden access and scientific progress for American patients. This agreement reflects our purpose to reach more patients as we expand our U.S. investment in additional research, development, and manufacturing to deliver breakthrough cancer treatments worldwide.” Improved access to oncol
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom